How will HEOR leaders respond to recent policy changes? A survey from Tufts and the Center for the Evaluation of Value and Risk in Health (CEVR) provides the answer. Of the n=57 respondents, approximately 2/3 were heads of their HEOR department and the remaining 1/3 had some other senior level HEOR role. While 29.8% of these HEOR leaders reported through the market access function, 38.6% reported through medical affairs.
The four key topics examined in the survey included HEOR leaders’ views on IRA drug price negotiations, PDAB, most favored nation (MFN), and the Institute for Clinical and Economic Review (ICER). What did they find?
The majority of respondents (68%) said they somewhat or strongly agreed that the Inflation Reduction Act (IRA) has driven a greater need for HEOR evidence generation (Figure 1). Eleven percent reported that their companies are prioritizing biologics over small molecules in response to IRAs, while 30% reported that their companies are delaying or changing research plans for additional indications… More than half of respondents expect Prescription Drug Affordability Boards (PDABs) to further increase demand for HEOR (57%) and real-world evidence (RWE) (61%).
Nearly 3 in 10 respondents said so mfn Drug launches in developed countries in the MFN reference basket will be delayed.
In terms of anticipated behavior regarding “most-favored-nation” (MFN) pricing policies, 29% reported that their companies would delay product launches or raise prices in other developed countries, 27% said their companies were lobbying the federal government to drop MFN proposals, and 39% said their companies would take no action (Figure 3).
Only one in four respondents thought ICER Was gaining importance.
Twenty-three percent of respondents strongly or somewhat agreed that the Institute for Clinical and Economic Review (ICER) was gaining importance, while 43% disagreed and 34% were neutral on the matter.
The full report can be read Here.
